NCT00053482 - Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults | Biotech Hunter

Enrollment

357

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

April 30, 2003

Study Completion Date

October 31, 2003

Conditions

Smallpox

Interventions

BIOLOGICAL

ACAM2000 Smallpox Vaccine

Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml

BIOLOGICAL

Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®

Group 5 dose: 1.0x10-8th PFU/ml

Trial Locations (3)

Bio-Kinetic Clinical Applications, Springfield

PRA International, Lenexa

Memorial Hospital of Rhode Island Division of Infectious Diseases, Pawtucket